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ABSTRACT
Ensuring patient safety and efficacy of medicines is one of the top challenges in health-care today. Numbers of adverse effects, drug interactions, and 
risk factors have been reported later in the years of drug release and hence postmarketing surveillance is today’s need. Pharmacovigilance (PV) is the 
important and vital part of clinical research dedicated to minimize the risk of drug-related events to patient. PV covers the science and practice related 
to the recognition, estimation, understanding, and anticipation of adverse effects of drugs or any other possible drug-related problems. The objective 
of this article is to provide a concise review on the importance of PV practice to ascertain and maintenance of rational use of drugs within the domain 
of pharmacotherapy. Thus, in summary, this review attempts to stress that systematic PV is essential to buildup reliable information network on 
the safety of medicines to boost confidence about their safety. The scientists, clinicians, pharmaceutical manufacturers, drug developers, regulators, 
public policy makers, patients, and the general public all have their own complementary roles in achieving what is envisaged.
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INTRODUCTION
Modern medicines have changed the way in which diseases are 
managed and controlled with systematic approach. However, in 
spite of all their benefits, evidence continues to mount that adverse 
reactions to medicines are a common, yet often preventable, cause of 
illness, disability and end with even death. Pharmacovigilance (PV) 
also known as drug safety, is the pharmacological science relating to 
the detection, assessment, understanding and prevention of adverse 
effects, particularly long- and short-term side effects of medicines and 
traditional medicines [1].
It is extensively acknowledged that a drug has to go through various 
phases of clinical trial to establish its safety and efficacy before it is 
marketed commercially. PV is a very imperative and indivisible part 
of clinical research. Both clinical trials safety and postmarketing PV 
(popularly known as Postmarketing studies or Phase IV clinical trials) 
are critical throughout the product life cycle. However, the clinical 
trials propose various limitations such as strict criteria of inclusion and 
exclusion make it to be used in a very selective group of patients; special 
population groups such as children, pregnant woman, and old age 
population are not studied during the trials; and other factors causing 
drug reactions such as genetic factors, environmental factors, and drug-
drug interactions may not have been studied during the clinical trials. 
No medicine is absolutely free from harmful effects and polypharmacy 
increases the risk of reactions related to drug use, adverse drug reactions 
(ADRs), and ADRs as consequence of drug-drug interactions [4].
PV plays significant various roles such as, identification, quantification, 
and documentation of drug-related problems which are responsible 
for drug-related injuries. Further, National PV Programmes (NPP) have 
been introduced which occupies a key role in increasing the public 
awareness about drug safety. 5 years roadmap of PV Programme of India 
with initiation phase in 2010 followed by expansion with consolidation, 
maintenance, optimization, and finally achieved stage of excellence in 
2015 with creation of center of excellence for PV in Asia Pacific [1,2].
PV program organized with the broad objective as:
•	 The	short-term	objective	is	to	foster	a	reporting	culture
•	 The	intermediate	objective	is	to	involve	a	large	number	of	healthcare	
professionals in the systems for information provision (reporting) 




Once the product is manufactured and marketed overall safety of 
medicine is unknown, and postmarketing surveillance necessitates 
on the priority basis. To allay inappropriate or unsafe use of medicine, 
minimize unnecessary patient suffering and financial loss of patient, its 
today’s need to establish effective monitoring system as PV to reshape 
and ensure patient safety with involvement and support of health-
care professionals - doctors, pharmacists, nurses, and other health 
professionals in the country. The Department of Health’s Essential 
Drug Programme is dedicated to improving drug safety through ADR 
monitoring system. Through the NPP, adverse reactions expected 
should be reported on a daily basis in proper channels.
PV Programme of India (PVPI) was launched in July 2010 with purpose 
to ensure that the benefits of use of medicine prevail over the risks and 
thus defend the health of the Indian population.
•	 Improve	patient	care	and	safety	in	respect	to	the	use	of	medicines,	







•	 Contribute	 to	 the	assessment	of	benefit,	 adverse	effect,	 efficacy	
and hazard of medicines, promoting their safe, rational, and more 
effective (including cost-effective) use
•	 Promote	understanding,	education,	clinical	 training	 in	PV,	and	 its	
effective communication to the public [2].
NEED OF PV
Patient suffering with many different diseases, using several other drugs 
simultaneously, different lifestyle, traditions, and diet react to medicines. 
Different brands of medicines possess diversity in manufacturing 
and ingredients exploited. The ADRs and poisonings associated with 
traditional and herbal remedies also need to be monitored in each 
country. With the severity of adverse events related with drugs its need 
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hour to acquaint with the PV system for patient safety. PV is prime 
tool that will reshape patient safety after postmarketing surveillance. 
Concerns	focusing	on	need	of	PV	as	mentioned	below:
•	 Humanity	 concern	 -	 Insufficient	evidence	of	 safety	 from	clinical	
trials, animal experiments, and Phase 1-3 studies before marketing 
authorization
•	 Medicines	 are	 supposed	 to	 save	 lives,	 i.e.,	 dying	 from	disease	




Ethics to know of something that is harmful to another person; who 
does not know and not telling is unethical [2,3].
CONSEQUENCES OF MEDICINES
Since from longer time drugs effectively used to treat and prevent illness 
and have modernized health-care system. As one coin has two sides every 
drug has its benefits and side effects no any medicine is free from harmful 
effects and polypharmacy increases ADR and reactions related to drugs 
including drug-drug interactions. In general for society and individuals, 
ADRs due to drug interaction pose a serious health problem [1].
As per WHO, an adverse reaction (ADR) is defined as any response to a 
drug which is noxious and unintended and occurs at doses used in man 
for diagnosis, prophylaxis, and treatment. Gastrointestinal bleedings, 
central nervous system complications, cardiovascular disorders, and 
hemorrhages are the most commonly occurring ADRs for patient 
that takes place after administration of respective drug. Drug-related 
administrations causing ADRs some of pharmacological classes include 
nonsteroidal anti-inflammatory drugs (NSAIDs), antithrombotic drugs, 
sedatives, and cardiovascular agents including cardiac stimulants, and 
antiarrhythmics [2,3].
Drug-drug interaction occurs when two drugs are administered 
simultaneously or prior administration of another drug results in 
alteration of effect of one drug. In general, drug-drug interaction explains 
the effect of one drug changed either enhanced or reduced in the 
presence of another drug, herbal drug, food, drink or by environmental 
chemicals. The effects of drug combination may be synergistic or 
additive; antagonistic or reduced; or altered or idiosyncratic, and it 
may result in beneficial effects or adverse reactions. An adverse drug 
interaction is a drug-drug combinations causing ADR or therapeutic 
failure of one of drug. Drug interaction mechanism divided into two 
main groups pharmacokinetic and pharmacodynamic, depending 
on behavior of drug in body [3]. One of the most popular clinically 
important interactions discovered were food-drug interaction between 
patient consuming cheeses and monoamine oxidase (MAO) inhibitors 
resulting in hypertensive crises.
During the hospital stay, it was found from survey that the majority 
of drug-related reactions were pharmacodynamic (91.7%), 
pharmacokinetic (5.3%), and had both (3%). Potentially serious drug 
interactions reported with drugs are cardiovascular agents (e.g. enalapril, 
digoxin, furosemide) and anti-inflammatoric drugs (acetylsalicylic acid 
and other NSAIDs (diclofenac) and anticoagulants (such as warfarin). 
Fatal and serious reactions have been reported for more number of 
times for anticoagulants and antiplatelets. One of the specific herbal 
drug and their adverse effect include if ginko biloba adverse effect of 
bleeding taken along with aspirin it retards absorption of aspirin [4]. It 
is provoked that polypharmacy enhances the risk of adverse reactions 
related to drug use, and ADRs as consequence of drug interactions.
PROCESS OF PV
•	 What	to	report
 The NPP shall encourage reporting of all suspected drug related 
adverse events, including those suspected to have been caused 
by herbal, and traditional or alternative remedies [5].






affecting a patient’s management, including reactions suspected 
of causing: Death, Life-threatening, hospitalization, disability, 
congenital anomaly, and required intervention to prevent permanent 
impairment or damage.
•	 Who	can	Report?
 Any health care professionals (Doctors including Dentists, 
Nurses, and Pharmacists) may report suspected adverse 
drug events. The program shall not accept reports from lay 
members of the public or anyone else who is not a health-care 
professional [5,6].
•	 Where	to	Report?
 After completion, the form shall be returned/forwarded to the 
same PV center from where it was received. Reporting can be 
conducted to any one of the country vide PV centers nearest to 
the reporter (complete list of PV centers is available at: www.
cdsco.nic.in). In case of doubt, the form may be sent to the 
national	PV	center	at:	CDSCO,	New	Delhi	[7,8].
WHAT HAPPENS TO THE INFORMATION SUBMITTED?
Information submitted to the center of PV in a prescribed format shall be 
handled in strict confidence. Peripheral PV centers forward adverse event 
form to the Respective Regional PV centers for the purpose of causality 
analysis. This information shall be preceded to the Zonal PV centers. Data 
obtained will be analyzed statistically and forwarded to the global PV 
database	managed	by	WHO	Uppsala	Monitoring	Centre	in	Sweden.	The	
final report based on the analyzed data will be periodically reviewed by 
the	National	PV	Advisory	Committee	constituted	by	the	Ministry	of	Health	
and	Family	Welfare.	The	Committee	is	entrusted	with	the	responsibility	
to review data and suggest any regulatory interventions that may be 
required with respect to the drug/drugs or class of drugs [9,10].
•	 Process	of	PV
 The process of PV starts from collection and record of data and 




	 Collect	and	 record	of	AEs/ADRs	 integral	part	of	PV	process.	
Spontaneous reporting system (SRS) is the basic and broadly 
used method to report ADRs. It has great importance to identify 
ADRs yet under-reporting remains the major limitation, accounts 
for 90-95%. Other limitations include quality of report, reporting 
bias, and reporting only short latency events. SRS is effective 
way for ADRs reporting and able to safeguard the patient safety. 
A variety of reasons counted for under-reporting as reporting 
considered as additional burden as little obvious or immediate 
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A national ADR or PV advisory committee provides assistance on 
causality assessment, risk management, risk management case 
investigation, and crisis communication.
Most case reports suspected ADRs is the intrinsic problem in PV. 
Adverse reactions are rarely specific for the drug, diagnostic tests are 
usually absent and a recalling is rarely ethically justified. In practice few 
adverse reactions are “certain” or “unlikely;” most are somewhere in 
between these extremes, i.e., “possible” or “probable.” To cope up with 
this problem many systems have been developed for structured and 
balanced assessment of causality. None of these systems, however, have 
been shown to produce a precise and reliable quantitative estimation of 
relationship likelihood. Nevertheless, causality assessment has become 
a common routine procedure in PV. The advances and limitations of 
causality	 assessment	 are	 reviewed.	 The	 WHO-UMC	 system	 has	 been	
developed	in	consultation	with	the	National	Centers	participating	in	the	
Programme for International Drug Monitoring and is meant as a practical 
tool for the assessment of case reports [15,16]. It is basically a combined 
assessment taking into account the clinical pharmacological aspects of 








will propose evolutionary report either based on one man’s 
meat is another man’s poison. It will bring signal on reported 
information casual alert relationship between adverse event and 
drug or unknown relationship or incomplete documentation. 
Suggest warning and alert for regulatory agencies for patient 
safety	[8].
•	 Communicate	for	safe	use	of	drugs	among	stakeholders	[9,10]
	 Communicate	 regarding	 AEs	 of	 drugs	 among	 various	
stakeholders – Patient, physician and medical association, 
pharmaceutical industry and association, policy maker, press 
and public for minimizing suffering and creating awareness.
PARTNERS INPHARMACOVIGILANCE
Key players of PV in national drug policyare: Government, industry, 
hospitals and academia, medical and pharmaceutical associations, 
poisons and medicines information centers, health professionals, 
patients, consumers, media and World Health Organization, Uppsala 
monitoring	centre	[8].
ROLE AND RESPONSIBILITIES
National PV center will be responsible for the development of PV in 
the public health system. It promotes PV in the PHPs and sensitizes 
professionals and public health staff to the reporting of adverse 
reactions and irrational use of medicines to ensure patient safety.
Pharmacist
•	 Participate	in	spontaneous	reporting	of	adverse	events,	also	report	
(even if no adverse event)
•	 Evaluation	and	reporting	of	medication	errors	with	respect	to	drug	










Patients and the public
The patient adherence to pharmacotherapy is of prime importance 
for efficient recovery. Public awareness about adverse event, early 
reporting, and management are crucial to make sure patient confidence 
and compliance. The patient reporting of ADR considered as part of 
feedback communication link and need to be separate from involvement 
of	patient	interest	group	[8,10].
Primary health-care workers
Public awareness about adverse reactions, early reporting and 
management are essential for ensuring patient confidence, in and 
adherence to, pharmacotherapy. It is the responsibility of the primary 
health-care provider to detect, investigate, manage, and report ADRs. 
These staff will need training on the importance of adverse reactions, 
diagnosis, basic principles of causality assessment, and the important 
elements of the adverse reactions reporting form [11].
Primary health-care workers
Ensuring and reshaping patient safety its responsibility of primary 
health-care provider is to detect, investigate, manage, and report 
ADRs. To cope up with the serious issue of ADRs staff need training 
on the importance of adverse reactions, diagnosis, basic principles 
of causality assessment, and the important elements of the adverse 
reactions	reporting	 form	including	patient	education.	Counseling	and	
explanation about adverse reaction will definitely promote patients’ 
confidence	 and	 adherence.	 Continuous	 guidance	 and	 encouragement	
is indispensable for reporting adverse reaction [12]. It is imperative to 
accomplish a positive attitude toward PV. To encourage reporting, the 








Health-care workers outside the government system should also 
report adverse reactions. These would include among others, non-
governmental	organizations,	and	Charitable	health	facilities	[15,16].
RECOMMENDATIONS
Based on these observations, there are several ways we can move 








The need of the hour is to educate the physicians and encourage 
them to analyze and report any adverse effect that occurs in a patient. 
The industry should take concrete steps to generate confidence and 
reliability for its products [19].
CONCLUSION
PV is the practical approach to ensure safety of drug and reshape patient 
safety. It plays an important role in meeting the challenges offered by 
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the increased range and potency of medicines. The success of any PV 
system lies in its ability to prevent further adverse events of drug on the 
basis of information received. This will be possible only when health 
care professionals are vitally alert to the onset or offset of any ADRs. 
They need to prioritize their contributions to make the PV program for 
medicines a success.
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